Resmed (RMD) Net Income towards Common Stockholders (2009 - 2026)

Resmed's Net Income towards Common Stockholders history runs 18 years deep, the most recent figure standing at $398.7 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 9.23% year-over-year to $398.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 15.71% YoY) and the FY2025 annual result came in at $1.4 billion, up 37.2% from the prior year.
• Net Income towards Common Stockholders was $398.7 million for Q1 2026 at Resmed, up from $392.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $398.7 million in Q1 2026 and bottomed at $179.0 million in Q1 2022.
• A 5-year average of $284.3 million and a median of $292.2 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 328.1% — and 2023, when it fell 7.16%.
• Resmed's Net Income towards Common Stockholders stood at $224.9 million in 2022, then fell by 7.16% to $208.8 million in 2023, then surged by 65.05% to $344.6 million in 2024, then gained by 13.92% to $392.6 million in 2025, then grew by 1.56% to $398.7 million in 2026.
• Business Quant data shows RMD's Net Income towards Common Stockholders at $398.7 million in Q1 2026, $392.6 million in Q4 2025, and $348.5 million in Q3 2025.